ESMO 2022


Tucatinib | Colorectal Cancer | 361P

Tucatinib Plus Trastuzumab in Patients (Pts) with HER2-positive Metastatic Colorectal Cancer (mCRC): Patient-Reported Outcomes (PROs) From Phase 2 Study MOUNTAINEER

Tucatinib | Colorectal Cancer | 438TIP

MOUNTAINEER-03: Phase 3 Study of Tucatinib, Trastuzumab, and mFOLFOX6 as Firstline Treatment in HER2+ Metastatic Colorectal Cancer (Trial in Progress)

Tucatinib | Colorectal Cancer | 376P

Impact of anti-EGFR Therapies on HER2-positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-analysis of Clinical Outcomes

Enfortumab Vedotin | Urothelial Cancer | LBA73

Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin (EV) Monotherapy or in Combination with Pembrolizumab (P) in Previously Untreated Cisplatin-ineligible Patients (pts) with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Tucatinib | Colorectal Cancer | LBA27

Additional Analyses of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC

Disitamab Vedotin | Urothelial Carcinoma | 1779TIP

Phase 2 Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin in Patients (pts) With HER2-Expressing Urothelial Carcinoma (RC48G001, Trial in Progress)